Numerous studies are still underway to understand the mechanisms underlying TRAIL resistance in ovarian cancer, including combination therapy with cytotoxic chemotherapy, retinoids, proteasome inhibitors, demethylating agents, Akt inhibitors, and EGFR inhibitors. This evidence concerns the gene EGFR and ovarian cancer.